My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 500124 | NSE: DRREDDY | Pharmaceuticals & Drugs | Large Cap
1. Is Dr. Reddys Laboratories Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr. Reddys Laboratories Ltd is a good quality company.
2. Is Dr. Reddys Laboratories Ltd undervalued or overvalued?
The key valuation ratios of Dr. Reddys Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Dr. Reddys Laboratories Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Dr. Reddys Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 18.1% | 17.8% | 16.5% | 8.1% | 5.8% | 10.7% | 11.5% | 10.1% | 9.4% | 19.2% | - | ||
| Value Creation Index ⓘ | 0.6 | 0.6 | 0.5 | -0.3 | -0.5 | -0.1 | 0.0 | -0.1 | -0.2 | 0.7 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 13,415 | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 25,256 | ||
| YoY Gr. Rt. % | - | 12% | 3.6% | -8.8% | 0.6% | 8.2% | 13.4% | 8.7% | 13.1% | 14.5% | - | ||
| Adj EPS ⓘ | 112.8 | 134 | 142.3 | 78.3 | 57.1 | 110.2 | 119.6 | 112.3 | 118.7 | 266.5 | 283.2 | ||
| YoY Gr. Rt. % | - | 18.8% | 6.2% | -45% | -27% | 93% | 8.5% | -6.1% | 5.7% | 124.5% | - | ||
| BVPS (₹) ⓘ | 457.3 | 572.9 | 731.5 | 734.7 | 752.4 | 840 | 932.3 | 1,052.6 | 1,146 | 1,389 | 1,471.5 | ||
| Adj Net Profit ⓘ | 1,919 | 2,282 | 2,427 | 1,297 | 947 | 1,830 | 1,987 | 1,868 | 1,976 | 4,437 | 4,723 | ||
| Cash Flow from Ops. ⓘ | 1,970 | 2,524 | 3,263 | 2,144 | 1,803 | 2,870 | 2,984 | 3,570 | 2,811 | 5,888 | - | ||
| Debt/CF from Ops. ⓘ | 2.3 | 1.7 | 1 | 2.3 | 2.8 | 1.3 | 0.7 | 0.9 | 1.2 | 0.2 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 7% | 11.6% | 12.1% | 14.5% | ||||||||
| Adj EPS ⓘ | 10% | 36.1% | 30.6% | 124.5% | ||||||||
| BVPSⓘ | 13.1% | 13.1% | 14.2% | 21.2% | ||||||||
| Share Price | 8.8% | 17.3% | 3.4% | 28.8% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 27 | 25.8 | 21.7 | 10.5 | 7.6 | 13.8 | 13.4 | 11.2 | 10.7 | 20.9 | 19.8 | |
| Op. Profit Mgn % ⓘ | 24.2 | 23.4 | 25.8 | 17.5 | 16.5 | 20.6 | 14.1 | 20.3 | 17.5 | 26.2 | 29.4 | |
| Net Profit Mgn % ⓘ | 14.3 | 15.2 | 15.5 | 8.9 | 6.4 | 11.9 | 11.3 | 9.8 | 9.2 | 18 | 18.7 | |
| Debt to Equity ⓘ | 0.6 | 0.4 | 0.3 | 0.4 | 0.4 | 0.3 | 0.1 | 0.2 | 0.2 | 0.1 | - | |
| Working Cap Days ⓘ | 185 | 187 | 193 | 212 | 222 | 214 | 207 | 213 | 216 | 212 | 0 | |
| Cash Conv. Cycle ⓘ | 116 | 122 | 128 | 140 | 137 | 130 | 126 | 132 | 135 | 131 | 0 | |
Return on Equity has increased versus last 3 years average to 19.80%
Sales growth is growing at healthy rate in last 3 years 12.09%
Net Profit is growing at healthy rate in last 3 years 30.63%
Sales growth is good in last 4 quarters at 23.58%
No data to display
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 225 | 283.2 |
| TTM Sales (₹ Cr.) | 18,362 | 25,256 |
| BVPS (₹.) ⓘ | 1,317.2 | 1,471.5 |
| Reserves (₹ Cr.) ⓘ | 21,885 | 24,458 |
| P/BV ⓘ | 4.12 | 3.69 |
| PE ⓘ | 24.11 | 19.16 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 4176.85 / 5986.20 |
| All Time Low / High (₹) | 6.25 / 5986.20 |
| Market Cap (₹ Cr.) | 90,490 |
| Equity (₹ Cr.) | 83.4 |
| Face Value (₹) | 5 |
| Industry PE ⓘ | 41.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dr. Reddy’s Laboratories Limited commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas. The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and on the New York Stock Exchange in the United States.
Business area of the company
The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.
Products
Core Businesses
Pharmaceutical services & active ingredients
Global Generics
Proprietary Products
Awards & Recognitions
Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
